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Non-ST-Elevation Myocardial Infarction in the United States:
Contemporary Trends in Incidence, Utilization of the Early
Invasive Strategy, and In-Hospital Outcomes
Sahil Khera, MD;* Dhaval Kolte, MD, PhD;* Wilbert S. Aronow, MD; Chandrasekar Palaniswamy, MD; Kathir Selvan Subramanian, MD;
Taimoor Hashim, MD; Marjan Mujib, MD, MPH; Diwakar Jain, MD; Rajiv Paudel, MD; Ali Ahmed, MD, MPH; William H. Frishman, MD;
Deepak L. Bhatt, MD, MPH; Julio A. Panza, MD; Gregg C. Fonarow, MD
Background-—There has been a paradigm shift in the deﬁnition of timing of early invasive strategy (EIS) for patients admitted with
non-ST-elevation myocardial infarction (NSTEMI) in the last decade. Data on trends of EIS for NSTEMI and associated in-hospital
outcomes are limited. Our aim is to analyze temporal trends in the incidence, utilization of early invasive strategy, and in-hospital
outcomes of NSTEMI in the United States.
Methods and Results-—We analyzed the 2002–2011 Nationwide Inpatient Sample databases to identify all patients ≥40 years of
age with the principal diagnosis of acute myocardial infarction (AMI) and NSTEMI. Logistic regression was used for overall, age-,
sex-, and race/ethnicity-stratiﬁed trend analysis. From 2002 to 2011, we identiﬁed 6 512 372 patients with AMI. Of these,
3 981 119 (61.1%) had NSTEMI. The proportion of patients with NSTEMI increased from 52.8% in 2002 to 68.6% in 2011 (adjusted
odds ratio [OR; per year], 1.055; 95% conﬁdence interval [CI], 1.054 to 1.056) in the overall cohort. Similar trends were observed in
age-, sex-, and race/ethnicity-stratiﬁed groups. From 2002 to 2011, utilization of EIS at day 0 increased from 14.9% to 21.8%
(Ptrend<0.001) and utilization of EIS at day 0 or 1 increased from 27.8% to 41.4% (Ptrend<0.001). Risk-adjusted in-hospital mortality
in the overall cohort decreased during the study period (adjusted OR [per year], 0.976; 95% CI, 0.974 to 0.978).
Conclusions-—There have been temporal increases in the proportion of NSTEMI and, consistent with guidelines, greater utilization
of EIS. This has been accompanied by temporal decreases in in-hospital mortality and length of stay. ( J Am Heart Assoc. 2014;3:
e000995 doi: 10.1161/JAHA.114.000995)
Key Words: early invasive strategy • in-hospital mortality • non-ST-elevation myocardial infarction • temporal trends
A cute coronary syndromes (ACS) continue to be a majorcause of morbidity and mortality.1 Data from the United
States and Europe have reported a decrease in the incidence
of ST-elevation myocardial infarction (STEMI) with an increase
in non-ST-elevation myocardial infarction (NSTEMI) in the past
decade.2–6 Current 2012 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines recom-
mend early invasive strategy (EIS) for management of patients
with NSTEMI and refractory angina or electrical or hemody-
namic insufﬁciency (class IB), initially stabilized patients with
NSTEMI, and high risk of clinical events (class IA). The early
invasive approach (within 12 to 24 hours of presentation) to
reduce ischemic complications is also recommended in
initially stabilized high-risk patients with NSTEMI (class IIA).7
The optimal timing of EIS has been debated and undergone a
paradigm shift in the last decade. The transition from
48 hours to within 24 hours occurred after the publication
of the Timing of Intervention in Acute Coronary Syndromes
(TIMACS) trial in 2009.8,9 However, there is a paucity of
information with regard to the secular trends in utilization of
EIS in patients with NSTEMI and how this may vary among
different NSTEMI patient populations. Using a large nation-
wide administrative database, the present study aimed to
analyze and describe age-, sex-, and race/ethnicity-speciﬁc
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trends in the incidence, utilization of EIS, and in-hospital
outcomes for NSTEMI in the United States from 2002 to
2011.
Methods
Data Source
Data were obtained from the 2002 to 2011 Nationwide
Inpatient Sample (NIS) databases. The NIS, sponsored by the
Agency for Healthcare Research and Quality as a part of the
Healthcare Cost and Utilization Project (HCUP), is the largest
publicly available all-payer inpatient care database in the
United States. It contains discharge-level data from 8 mil-
lion hospital stays from approximately 1000 hospitals
designed to approximate a 20% stratiﬁed sample of all
community hospitals in the United States. Criteria used for
stratiﬁed sampling of hospitals include hospital ownership,
bed size, teaching status, urban or rural location, and
geographic region. Discharge weights are provided for each
patient discharge record, which were used to obtain national
estimates. Discharge weights are calculated for NIS data by
ﬁrst stratifying the NIS hospitals on the same variables used
for creating the sample. A weight is then calculated for each
stratum by dividing the number of universe discharges in that
stratum (obtained from American Hospital Association data)
by the number of NIS discharges in the stratum. Weighted
estimates are calculated by uniformly applying stratum
weights to the discharges according to the stratum from
which the discharge was drawn. Weights are assigned to each
discharge and are stored in each record in the data element,
DISCWT. When the discharge weights are applied to the
unweighted NIS data, the result is an estimate of the number
of discharges for all inpatient discharges from community
hospitals in the United States. This study was deemed exempt
by the New York Medical College Institutional Review Board
(Valhalla, NY) because HCUP-NIS is a public database with no
personal identifying information.
Study Population
We used the International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation (ICD-9-CM), codes 410.xx to
identify all patients ≥40 years of age with the principal
diagnosis of acute myocardial infarction (AMI; N=6 512 372).
Patients with the principal diagnosis of NSTEMI were then
identiﬁed using ICD-9-CM codes 410.7x (n=3 981 119). We
chose the principal diagnosis because it is considered the
primary reason for hospital admission. EIS was deﬁned as
coronary angiography (ICD-9-CM procedure codes 88.55,
88.66, 37.22, or 37.23) with or without revascularization
(ie, percutaneous coronary intervention (PCI; ICD-9-CM
procedure codes 00.66, 36.01, 36.02, 36.05, 36.06 and
36.07) or coronary artery bypass graft surgery (CABG; ICD-9-
CM procedure code 36.1x) on day 0 (considered within
24 hours of admission) or on days 0 or 1 (considered within
48 hours of admission).
Outcomes Measured
We initially studied the overall age-, sex-, and race/ethnicity-
speciﬁc trends in the incidence of NSTEMI. We then examined
the trends in utilization of the EIS in patients with NSTEMI.
Our primary outcome of interest was all-cause, in-hospital
mortality, deﬁned as death during the hospitalization encoun-
ter in the NIS database. We used the average length of stay
and total hospital cost as secondary outcomes. We analyzed
the overall age-, sex-, and race/ethnicity-speciﬁc trends in
utilization of the EIS, risk-adjusted in-hospital mortality,
average length of stay, and total hospital cost in patients
with NSTEMI. The NIS provides total charges, which reﬂect
the amount a hospital billed for services, rather than actual
costs or the amount a hospital received in payment. In this
study, we used the HCUP Cost-to-Charge Ratio File developed
by the Agency for Healthcare Research and Quality (AHRQ) to
translate total charges into costs. Each ﬁle contains hospital-
speciﬁc cost-to-charge ratios based on all-payer inpatient cost
for nearly every hospital in the NIS databases. Cost information
Table 1. International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation (ICD-9-CM) and Clinical
Classiﬁcations Software (CCS) Codes Used to Identify
Comorbidities
Comorbidities Source Code(s)
Smoking ICD-9-CM V15.82, 305.1
Dyslipidemia CCS 53
Coronary artery disease ICD-9-CM 414.00-414.07
Family history of coronary
artery disease
ICD-9-CM V17.3
Previous myocardial
infarction
ICD-9-CM 412
Previous transient
ischemic attack/stroke
ICD-9-CM V12.54
Previous percutaneous
coronary intervention
ICD-9-CM V45.82
Previous coronary artery
bypass grafting
ICD-9-CM V45.81
Carotid artery disease ICD-9-CM 433.10
Atrial fibrillation ICD-9-CM 427.31
Dementia ICD-9-CM 290.xx, 294.1x, 294.2x,
294.8, 331.0-331.12,
331.82, 797
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is obtained from the hospital accounting reports collected by
the Centers for Medicare and Medicaid Services.
Patient and Hospital Characteristics
Baseline patient characteristics used included demographics
(age, sex, race/ethnicity, primary expected payer, weekday
versus weekend admission), 29 Elixhauser co-morbidities as
deﬁned by the AHRQ and other clinically relevant comor-
bidities (smoking, dyslipidemia, known coronary artery
disease [CAD], family history of CAD, previous myocardial
infarction [MI], previous transient ischemic attack or stroke,
previous PCI, previous CABG, carotid artery disease,
dementia, and atrial ﬁbrillation). A list of ICD-9-CM and
Clinical Classiﬁcations Software codes used to identify
comorbidities and in-hospital procedures is provided in
Table 1. Hospital characteristics, such as hospital region
(Northeast, Midwest, South, and West), bed size (small,
medium, and large), location (rural or urban), and teaching
status were also included.
Statistical Analysis
Weighted data were used for all statistical analyses. For trend
analysis, we used Mantel-Haenszel’s chi-square (v2) test of
linear association for categorical variables and linear
regression for continuous variables. To assess whether the
incidence of NSTEMI, utilization of EIS, or in-hospital mortality
has changed over time, unadjusted and multivariable adjusted
logistic regression models were constructed. Our independent
variable, calendar year, was initially entered as a continuous
variable in the regression models to obtain unadjusted and
adjusted odds ratios (ORs; per year) for the temporal trends.
To determine whether there was a temporal variability from
year to year in the incidence of NSTEMI, utilization of EIS, or
in-hospital mortality, we also evaluated calendar year as a
categorical variable, with 2002 as the reference year. The
regression models adjusted for all demographics (except sex
and race/ethnicity for sex and race/ethnicity-speciﬁc trends,
respectively), hospital characteristics, and all Elixhauser and
other clinically relevant comorbidities. The methodology has
been utilized in our previous analysis of NIS databases.10,11
We graphically displayed the unadjusted and adjusted ORs
and 95% conﬁdence intervals (CIs) for incidence of NSTEMI,
utilization of EIS for NSTEMI, or in-hospital mortality over
time.
Statistical analysis was performed using IBM SPSS
Statistics 20.0 (IBM Corp., Armonk, NY). All P values were
2 sided with a signiﬁcance threshold of P<0.001 (a lower-
than-usual P-value threshold was selected to correct for
the effects of a large sample size as well as inﬂation of
type I error because of repeated testing using a large
number of variables). Categorical variables are expressed as
percentage and continuous variables as mean SEM. OR,
and 95% CI were used to report the results of logistic
regression.
Results
Temporal Trends in NSTEMI
From 2002 to 2011, we identiﬁed 6 512 372 patients
≥40 years of age admitted with AMI. Of these, 3 981 119
(61.1%) had NSTEMI. Among patients with AMI, the proportion
of those presenting with NSTEMI increased from 52.8%
in 2002 to 68.6% in 2011 (Ptrend<0.001). After adjusting
for baseline demographics, hospital characteristics, and
A
B
Figure 1. Temporal trends in incidence of non-ST-elevation
myocardial infarction (STEMI). A, NSTEMI (%) was calculated as
the number of patients with NSTEMI divided by the number of
patients with acute myocardial infarction (AMI) per year9100;
Ptrend<0.001. B, Trends in NSTEMI presented as unadjusted and
adjusted odds ratio and 95% conﬁdence interval (CI) for each year
relative to 2002 (reference year). Regression model adjusted for
demographics, hospital characteristics, and 29 Elixhauser and
other clinically relevant comorbidities. 95% CIs are depicted, but
are too narrow to be visualized outside the marker width.
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comorbidities, we observed an increasing trend in the
proportion of patients hospitalized with NSTEMI from 2002
to 2011 (adjusted OR [per year], 1.055; 95% CI, 1.054 to
1.056; P<0.001; Figure 1; Table 2).
The increase in proportion of NSTEMI was observed in all
age groups. During the study period, it increased from 45.4%
to 60.2% in those 40 to 64 years of age (adjusted OR [per
year], 1.045; 95% CI, 1.044 to 1.046; P<0.001), from 54.5% to
70.7% in those 65 to 74 (adjusted OR [per year], 1.056; 95%
CI, 1.055 to 1.058; P<0.001), and from 59% to 77.1% in
patients ≥75 (adjusted OR [per year], 1.066; 95% CI, 1.065 to
1.068; P<0.001). When stratiﬁed according to sex, women
(56.1% to 73.6%; adjusted OR [per year], 1.070; 95% CI, 1.069
to 1.071; P<0.001) had a steeper proportional increase,
compared to men (50.4% to 65.3%; adjusted OR [per year],
1.046; 95% CI, 1.045 to 1.047; P<0.001). Increase in NSTEMI
proportions were also observed across all races. African-
American patients showed the greatest proportional increase
(Figure 2; Table 2).
Changing Baseline Characteristics of Patients
With NSTEMI
Table 3 depicts the baseline demographic, hospital, and
clinical characteristics of patients admitted with NSTEMI from
2002 to 2011. There was a slight decrease in mean age at
admission during the study period (70.3613.11 years in
2002 versus 69.8713.53 in 2011; P<0.001). More specif-
ically, there was an increase in the proportion of NSTEMI
patients aged 40 to 64 years and decrease in those aged
≥75 years from 2002 to 2011 (Ptrend<0.001). Similarly, there
was a small, but statistically signiﬁcant, increase in the
proportion of men (56% in 2002 to 57.5% in 2011;
Ptrend<0.001) and a consequent decrease in the proportion
of women (44.0% in 2002 to 42.5% in 2011; Ptrend<0.001)
with NSTEMI during the study period. The prevalence of
smoking, dyslipidemia, CAD, previous MI, carotid artery
disease, diabetes mellitus, hypertension, obesity, peripheral
vascular disease, chronic renal failure, alcohol abuse, deﬁ-
ciency anemias, coagulopathy, ﬂuid/electrolyte disorders, and
previous PCI increased from 2002 to 2011 (Ptrend<0.001 for
all). The prevalence of heart failure and chronic pulmonary
diseases remained relatively constant throughout the study
period.
Trends in EIS
Utilization of EIS on day 0 of presentation increased from
14.9% in 2002 to 21.8% in 2011 (adjusted OR [per year],
1.065; 95% CI, 1.064 to 1.066; P<0.001). The adjusted
temporal trends for utilization of EIS were similar across all
age, sex, and racial/ethnic groups. Patients ≥75 years of age
had the highest proportional increase in utilization of EIS
(adjusted OR [per year], 1.072; 95% CI, 1.069 to 1.074;
P<0.001; Figures 3 and 4; Table 4).
We also analyzed the utilization of EIS at day 0 or 1.
Results showed a temporal increase in the overall as well as
the age-, race/ethnicity-, and sex-stratiﬁed cohorts (Figures 3
and 4; Table 5).
A
B
C
Figure 2. Age, sex, and race/ethnicity speciﬁc trends in
incidence rates of non-ST-elevation myocardial infarction. A, Age
stratiﬁed; Ptrend<0.001, (B) sex stratiﬁed; Ptrend<0.001, and
(C) race/ethnicity stratiﬁed; Ptrend<0.001. AMI indicates acute
myocardial infarction; NSTEMI, non-ST-elevation myocardial
infarction.
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Table 3. Baseline Demographics, Hospital Characteristics, Comorbidities, Utilization of Early Invasive Strategy, and Overall
In-Hospital Mortality in Patients With Non-ST-Elevation Myocardial Infarction
Variable 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 P Value
No. of cases (weighted) 393 937 405 415 390 093 384 392 395 477 384 373 406 566 412 679 397 624 410 563 —
Age (mean, y) 70.36 70.40 70.29 70.32 69.83 69.90 70.19 69.66 69.72 69.87 <0.001
Age-stratified cases, y
(% of total)
<0.001
40 to 64 32.8 33.3 33.8 34.4 36.0 36.0 35.4 37.0 37.2 36.7
65 to 74 24.1 23.3 23.4 22.4 22.4 22.8 22.4 23.0 22.9 23.4
≥75 43.1 43.4 42.8 43.3 41.6 41.2 42.2 40.0 39.9 39.9
Gender, % <0.001
Men 56.0 56.1 56.4 56.5 56.8 56.4 56.4 57.2 57.1 57.5
Women 44.0 43.9 43.6 43.5 43.2 43.6 43.6 42.8 42.9 42.5
Race, % <0.001
White 79.2 77.4 78.3 79.6 77.4 76.2 77.0 76.1 75.4 74.8
African American 9.2 9.3 9.7 7.8 9.4 10.6 9.6 9.7 12.3 11.7
Hispanic 6.5 8.5 7.0 7.5 7.9 7.1 6.6 7.3 6.8 7.9
Asian/Pacific Islander 1.8 2.1 2.1 1.7 1.9 2.4 2.4 2.1 2.3 2.0
Other 3.2 2.7 2.8 3.5 3.4 3.8 4.8 3.3 3.4 3.5
Primary expected payer, % <0.001
Medicare 65.7 66.4 64.8 65.5 63.5 62.8 62.9 62.3 62.3 64.0
Medicaid 4.0 4.6 4.5 4.9 4.7 4.7 5.1 5.6 6.1 5.7
Private insurance 25.3 23.8 24.6 23.7 25.0 25.2 24.7 24.1 23.8 22.6
Uninsured 2.8 3.0 3.7 3.8 4.0 4.3 4.3 5.1 5.0 4.8
Other 2.2 2.2 2.4 2.2 2.8 3.0 3.0 2.9 2.8 2.9
Weekend admission, % 24.8 24.3 24.7 24.8 24.3 24.7 25.6 25.3 25.7 25.7 <0.001
Hospital characteristics
Region, % <0.001
Northeast 24.1 23.6 23.3 24.1 23.1 21.7 19.0 20.6 20.5 19.6
Midwest 21.1 23.0 23.3 20.4 21.9 23.0 24.7 22.2 24.8 21.7
South 39.5 38.8 37.7 39.8 40.5 39.3 40.1 41.3 38.2 40.5
West 15.4 14.6 15.7 15.7 14.5 16.0 16.2 15.9 16.5 18.2
Bed size, % <0.001
Small 9.4 9.7 10.2 7.0 11.1 9.4 10.3 8.9 10.1 9.9
Medium 24.4 25.0 23.7 24.6 25.1 25.2 23.1 21.9 21.8 24.1
Large 66.2 65.3 66.1 68.4 63.8 65.4 66.7 69.1 68.1 66.0
Urban location 86.6 86.8 89.1 89.9 90.7 89.2 88.7 89.6 88.1 89.8 <0.001
Teaching hospital 43.8 44.4 46.8 45.4 51.1 49.3 45.4 47.3 46.5 47.9 <0.001
Comorbidities, %
Smoking 20.5 20.1 21.6 23.9 25.4 27.0 27.9 31.8 33.0 35.0 <0.001
Dyslipidemia 35.6 36.5 40.3 43.8 47.4 50.6 52.4 56.4 59.2 62.1 <0.001
CAD 68.2 68.8 69.6 70.5 72.0 72.0 72.9 76.2 75.9 77.4 <0.001
Family h/o CAD 3.3 3.2 4.0 4.9 5.0 5.7 6.0 7.3 8.2 8.3 <0.001
Previous myocardial
infarction
8.9 8.5 9.1 9.0 9.7 10.2 10.5 11.6 12.3 13.1 <0.001
Continued
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Table 3. Continued
Variable 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 P Value
Previous TIA/stroke* — — — — — 0.8 4.4 5.9 6.7 7.4 <0.001
Previous PCI 7.0 7.0 7.2 7.8 9.1 10.0 10.7 12.4 13.5 15.5 <0.001
Previous CABG 9.2 8.9 8.6 8.3 8.5 8.4 8.8 9.7 9.8 10.9 <0.001
CAD 1.3 1.3 1.3 1.4 1.6 1.8 2.1 2.4 2.4 2.7 <0.001
Atrial fibrillation 18.5 18.5 18.4 18.9 19.0 18.5 17.1 17.8 18.1 19.2 <0.001
Dementia 5.1 5.4 5.5 5.8 6.0 6.2 7.1 7.1 7.3 7.8 <0.001
AIDS 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 <0.001
Alcohol abuse 1.8 1.8 2.0 2.1 2.4 2.4 2.5 2.7 2.8 2.8 <0.001
Deficiency anemias 11.9 12.6 12.4 12.7 13.5 15.8 17.7 18.3 18.5 20.3 <0.001
RA/collagen vascular
diseases
1.8 1.7 1.8 1.9 2.0 2.1 2.3 2.3 2.4 2.6 <0.001
Chronic blood loss
anemia
1.6 1.6 1.6 1.7 1.7 1.7 1.3 1.2 1.0 1.0 <0.001
Congestive heart failure 35.2 36.1 37.0 36.6 34.6 34.6 34.0 34.4 34.9 35.5 <0.001
Chronic pulmonary
disease
22.2 22.2 22.2 23.3 23.0 23.5 22.9 22.9 22.5 23.6 <0.001
Coagulopathy 2.8 3.1 3.4 3.4 3.5 3.9 3.8 4.6 4.8 5.5 <0.001
Depression 3.9 4.3 4.4 4.9 5.3 6.0 6.7 7.1 7.5 8.1 <0.001
Diabetes
(uncomplicated)
27.0 27.7 27.5 27.3 28.4 29.1 29.6 30.4 30.9 31.8 <0.001
Diabetes (complicated) 6.1 6.1 6.0 6.1 6.0 6.9 7.1 7.0 7.3 8.3 <0.001
Drug abuse 0.7 0.8 1.0 1.2 1.4 1.5 1.4 1.7 1.8 1.9 <0.001
Hypertension 51.0 59.3 61.0 62.4 65.5 66.7 69.3 71.2 72.6 74.3 <0.001
Hypothyroidism 7.8 8.1 8.0 8.5 8.7 9.8 10.9 11.0 11.4 12.4 <0.001
Liver disease 0.7 0.7 0.9 0.9 0.9 1.1 1.1 1.2 1.3 1.4 <0.001
Lymphoma 0.5 0.4 0.5 0.5 0.5 0.5 0.6 0.5 0.5 0.6 <0.001
Fluid and electrolyte
disorder
14.5 15.5 16.3 17.5 17.7 18.9 20.4 20.5 20.9 22.6 <0.001
Metastatic cancer 0.8 0.7 0.9 0.9 0.9 1.0 1.0 1.0 0.9 1.0 <0.001
Other neurological
disorders
5.6 5.1 5.1 5.3 5.6 6.1 6.7 6.7 6.5 6.9 <0.001
Obesity 6.6 6.7 7.0 7.6 8.1 9.5 11.1 12.4 12.1 14.2 <0.001
Paralysis 1.9 1.8 1.7 1.6 1.7 1.8 2.3 1.9 1.9 2.0 <0.001
Peripheral vascular
disease
9.5 9.7 10.2 10.0 10.9 12.2 12.7 13.3 12.7 14.2 <0.001
Psychoses 1.3 1.4 1.4 1.4 1.5 1.7 2.2 2.2 2.4 2.7 <0.001
Pulmonary circulation
disorders
0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 <0.001
Renal failure (chronic) 8.5 9.4 9.6 11.9 17.9 20.4 20.1 21.6 22.8 24.8 <0.001
Solid tumor without
metastasis
6.7 1.4 1.5 1.5 1.5 1.6 1.6 1.6 1.6 1.6 <0.001
Peptic ulcer
(nonbleeding)
1.5 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <0.001
Valvular disease 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 <0.001
Weight loss 1.1 1.3 1.4 1.4 1.5 1.8 2.4 2.7 2.6 3.3 <0.001
Continued
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Primary Outcome: In-Hospital Mortality
In-hospital mortality decreased from 5.5% in 2002 to 3.9% in
2011 in all patients with NSTEMI (adjusted OR [per year],
0.976; 95% CI, 0.974 to 0.978; P<0.001). On age-stratiﬁed
analysis, those ≥75 years of age had the greatest decrease in
in-hospital mortality (adjusted OR [per year], 0.968; 95% CI,
0.966 to 0.971; P<0.001). Women had a steeper temporal
decline in in-hospital mortality, compared to men, from 2002
to 2011 (adjusted OR [per year], 0.965; 95% CI, 0.962 to
0.968; P<0.001 in women and adjusted OR [per year], 0.986;
95% CI, 0.984 to 0.989; P<0.001 in men). Statistically
signiﬁcant decline in mortality was also observed in all racial/
ethnic groups.
In patients receiving EIS on day 0 of presentation, in-
hospital mortality was 2.5% in 2002 and 2.0% in 2011.
However, the overall trend in this decrease was not statis-
tically signiﬁcant (adjusted OR [per year], 0.998; 95% CI,
Table 3. Continued
Variable 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 P Value
Invasive strategy, %
Day 0 14.9 15.5 17.0 18.2 21.0 20.0 19.8 23.1 21.9 21.8 <0.001
Day 0 or 1 27.8 29.2 31.1 33.3 36.4 35.2 35.3 41.1 40.9 41.4 <0.001
In-hospital mortality, % 5.5 5.5 5.2 4.9 4.6 4.4 4.4 4.1 4.0 3.9 <0.001
AIDS indicates acquired immunodeﬁciency syndrome; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; h/o, history of; PCI, percutaneous coronary intervention;
RA, rheumatoid arthritis; TIA, transient ischemic attack.
*Data for previous transient ischemic attack/stroke were available from 2007.
A B
C D
Figure 3. Trends in utilization of early invasive strategy for non-ST-elevation myocardial infarction.
A, Early invasive strategy at day 0; Ptrend<0.001. B, Trends in early invasive strategy at day 0 presented as
unadjusted and adjusted odds ratio and 95% conﬁdence interval (CI) for each year relative to 2002
(reference year). Regression model adjusted for demographics, hospital characteristics, and 29 Elixhauser
and other clinically relevant comorbidities. C, Early invasive strategy at day 0 or 1; Ptrend<0.001. D, Trends
in early invasive strategy at day 0 or 1 presented as unadjusted and adjusted odds ratio and 95% conﬁdence
interval (CI) for each year relative to 2002 (reference year). Regression model adjusted for demographics,
hospital characteristics, and 29 Elixhauser and other clinically relevant comorbidities. 95% CIs are depicted,
but are too narrow to be visualized outside the marker width. NSTEMI indicates non-ST-elevation myocardial
infarction.
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0.991 to 1.004; P=0.471). A temporal decline in in-hospital
mortality was observed in patients treated with invasive
strategy on day 0 or 1 (2.4% in 2002 to 1.8% in 2011;
adjusted OR [per year], 0.988; 95% CI, 0.983 to 0.993;
P<0.001; Figures 5 and 6; Table 6). In patients not receiving
EIS, in-hospital mortality decreased from 6.7% in 2002 to 5.4%
in 2011 (adjusted OR [per year], 0.977; 95% CI, 0.975 to
0.979; P<0.001; Figure 6; Table 6).
Secondary Outcomes: Cost and Length of Stay
For secondary outcome analysis, we studied the temporal
trends in cost and length of stay. Detailed results of the
length and cost of stay temporal trends stratiﬁed by age, sex,
and race/ethnicity are shown in Tables 7 and 8, respectively.
The mean (SEM, in days) length of stay decreased in the
overall cohort of patients during the study period (5.70.01
in 2002 to 4.80.01 in 2011; Ptrend<0.001). Patients with
NSTEMI undergoing EIS within day 0 had the shortest length
of stay, and the length of stay declined in all patients
undergoing EIS, irrespective of timing (from 4.40.03 in 2002
to 3.90.02 in 2011 for those with EIS at day 0 and
from 4.80.02 in 2002 to 4.10.01 in 2011 for those
with EIS within day 0 or 1; Ptrend<0.001 for all; Figure 7;
Table 7).
Mean (SEM, in dollars) cost of stay in the overall patient
population admitted with NSTEMI increased from
$14 77430 from 2002 to $20 26935 in 2011
(Ptrend<0.001). The mean (SEM, in dollars) costs accrued
by those undergoing EIS were higher and showed a similar
increasing trend (from $17 38580 in 2002 to $24 34576
in 2011 for those with EIS at day 0 and from $17 53459 in
2002 to $23 97155 in 2011 for those with EIS within day 0
or 1; Ptrend<0.001 for all; Figure 8; Table 8).
A
B
C
D
E
F
Figure 4. Age, sex, and race/ethnicity speciﬁc trends in utilization of early invasive strategy (EIS) for
non-ST-elevation myocardial infarction. A, Age stratiﬁed, EIS day 0; Ptrend<0.001, (B) sex stratiﬁed, EIS
day 0; Ptrend<0.001, (C) race/ethnicity stratiﬁed, EIS day 0; Ptrend<0.001, (D) age stratiﬁed, EIS day 0
or 1; Ptrend<0.001, (E) sex stratiﬁed, EIS day 0 or 1; Ptrend<0.001, and (F) race/ethnicity stratiﬁed, EIS day 0 or
1; Ptrend<0.001. NSTEMI indicates non-ST-elevation myocardial infarction.
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Discussion
We report an increasing trend in the proportion of NSTEMI
admissions for the overall cohort and in the age-, sex-, and
race/ethnicity-stratiﬁed subgroups from 2002 to 2011. This
is associated with an increase in utilization of EIS, decreased
in-hospital mortality, and decreased length of stay during the
same period.
Analysis of the National Registry of Myocardial Infarction
from 1990 to 2006 reported an increase in the proportion of
NSTEMI from 14.2% in 1990 to 59.1% in 2006 (P<0.001).2 The
proportional increase in NSTEMI may be the result of an aging
population, increasing chronic comorbidities, and reduction in
smoking. Part of the increase in the proportion of NSTEMI in
our study may be attributable to increased utilization and
higher sensitivity of cardiac biomarkers (troponins). In the
age- and sex-stratiﬁed analysis, patients ≥75 years and
women had the greatest proportional increase in NSTEMI.
Women are also more likely to present with NSTEMI,
compared to men.12 Older patients are more likely to be
women and have signiﬁcant comorbidities that predispose
them to NSTEMI.
On trend analysis of baseline characteristics, we report an
increase in the proportion of patients in the 40 to 64 years of
age group. This is in concordance with the analysis of Get
With The Guidelines Coronary Artery Disease Registry from
2003 to 2008,13 with that age group representing the fastest-
growing segment of our population over the years.
Importantly, there was a temporal increase in utilization of
the EIS in the NSTEMI patient population. Meta-analysis
of randomized, control trials has consistently shown a beneﬁt
of EIS in the setting of NSTEMI, especially in the high-risk
patient population.14,15 Deﬁnition of optimal timing of invasive
management has undergone a paradigm shift in the last
decade. The 2002 ACC/AHA guidelines for management of
NSTEMI16 and the 2007 ACC/AHA guidelines17 for manage-
ment of NSTEMI in the elderly patient population deﬁned the
EIS as routine cardiac catheterization within 48 hours of
presentation. The more recent TIMACS trial8 compared the
routine early intervention (≤24 hours of presentation; median
time, 14 hours) to delayed intervention (≥36 hours after
presentation; median time, 50 hours). There was no signiﬁ-
cant difference in the primary endpoint, other than in the
prespeciﬁed subgroup with high Global Registry of Acute
Coronary Events scores. After 6 months, they reported a 28%
relative reduction in secondary outcome of death, MI, and
refractory ischemia in the early intervention group (OR, 0.72;
95% CI, 0.58 to 0.89; P=0.003).
The results of the CRUSADE (Can Rapid Risk Stratiﬁcation
of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines) Quality
Improvement Initiative from 2000 to 2002 indicated that the
EIS (within 48 hours) was not utilized in a majority of high-risk
patients with NSTEMI.18 They reported male sex, ischemic
electrocardiographic changes, younger age, positive biomar-
kers, lack of congestive heart failure, lack of renal insufﬁ-
ciency, and white race as predictors of early invasive
management. We analyzed the trends in both day 0 and day
0 or 1 of presentation. Utilization of EIS at day 0 increased
from 14.9% in 2002 to 21.8% in 2011 (P<0.001), and
utilization of EIS at day 0 or 1 increased from 27.8% in 2002
to 41.4% in 2011 (P<0.001). The increase in utilization was
consistent among all age-, race/ethnicity-, and sex-stratiﬁed
subgroups after multivariable adjustment. Men had a higher
proportional increase in EIS at both day 0 and day 0 or 1 of
presentation. Previous studies have discussed the sex
differences in the invasive management of ACS, with women
being managed less aggressively than men.19,20
A
B
Figure 5. Trends in in-hospital mortality in patients with non-ST-
elevation myocardial infarction. A, In-hospital mortality (%) was
calculated as the number of patients who died during the
hospitalization divided by the number of patients with NSTEMI
per year9100; Ptrend<0.001. B, Trends in in-hospital mortality
presented as unadjusted and adjusted odds ratio (OR) and 95%
conﬁdence interval (CI) for each year relative to 2002 (reference
year). Regression model adjusted for demographics, hospital
characteristics, and 29 Elixhauser and other clinically relevant
comorbidities. NSTEMI indicates non-ST-elevation myocardial
infarction.
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Interestingly, patients ≥75 years of age had a higher
proportional increase in EIS at day 0 and patients 40 to
64 years of age had an overall higher proportional increase at
day 0 or 1. Chin et al.,21 using the linked CRUSADE registry
and Medicare and Medicaid claims data, reported an
increased utilization of evidence based NSTEMI care and
decline in in-hospital mortality in 2006, compared with 2003
(OR, 0.82; 95% CI, 0.67 to 1.00; P=0.045) in patients
≥65 years of age with NSTEMI. Recent trend analysis from
Denmark also reported an increase in initiation of coronary
angiography for ﬁrst-time NSTEMI admissions at 3 days from
18.2% in 2001 to 55.7% to 2009.22
We also report a decrease in risk-adjusted in-hospital
mortality and length of stay for patients admitted with
NSTEMI. The decline in in-hospital mortality was observed in
patients receiving EIS as well as those not receiving EIS. This
observation is consistent with improvement in, or better
adherence to, medical therapy, independent of EIS utilization.
The lower in-hospital mortality observed in the EIS-managed
patients is likely the result of patient selection bias, as
previously demonstrated by analysis of the CRUSADE regis-
try,18 and no causal association between EIS and in-hospital
mortality can be inferred from the results of our study.
The decline in overall in-hospital mortality was most
prominent in those ≥75 years of age. We have previously
reported a 24% relative reduction of in-hospital mortality in
octogenarians treated with the early invasive approach versus
the initial conservative strategy (OR, 0.76; 95% CI, 0.74 to
0.78; P<0.001).23 However, it is not possible to conclusively
establish a causal relationship between increasing utilization
of EIS and decreasing in-hospital mortality from this study.
Limitations
This study has certain limitations. Because this is a
retrospective, observational study, the possibility of selection
bias and residual measured and unmeasured confounding
cannot be completely eliminated. NIS is an administrative
database; there is the potential for unrecognized miscoding of
diagnostic and procedure codes. There is a possibility that
widespread troponin utilization in the last decade may have
contributed to the increase in NSTEMI diagnosis and also
potentially decreased case severity of those classiﬁed as
NSTEMI. Also, conditions other than ACS may have led to
troponin elevations and hence miscoding of NSTEMI exists.
Clinical presentation and medication utilization variables are
not available in this administrative database. It is our
assumption that day 0 corresponds to ≤24 hours and days
0 or 1 corresponds to ≤48 hours, because the database does
not provide the timing of procedure in hours. For trends in
A B
C D
Figure 6. Age, sex, race/ethnicity, and utilization of invasive strategy-speciﬁc trends in in-hospital
mortality in patients with non-ST-elevation myocardial infarction. A, Age stratiﬁed, (B) sex stratiﬁed,
(C) race/ethnicity stratiﬁed, and (D) stratiﬁed according to utilization of invasive strategy (Ptrend<0.001 for
all). No EIS was deﬁned as patients who did not receive coronary angiography with intent to revascularize
within day 0 or 1. EIS indicates early invasive strategy.
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total hospital costs, we did not convert hospital costs into
inﬂation-adjusted constant dollars. The NIS databases do not
include NSTEMI hospitalizations for veterans hospitalized in
Veterans Affairs hospitals. We could also not account for
patients transferred in from other hospitals. Last, outcomes in
the NIS database are limited to in-hospital events and causes
of death are not differentiated. However, these potential
limitations may be partially compensated by the large size of
the database and the ability to obtain nationwide estimates
using the discharge weights provided.
Conclusions
In this large, nationwide analysis of patients with MI, we
report an increase in proportion of NSTEMI with increasing
utilization of EIS in the United States. We also report a
decrease in in-hospital mortality and decrease in length of
stay during the study period. The improved outcomes may
reﬂect greater adherence to the evolving guideline-recom-
mended therapies. Nevertheless, age-, sex-, and race/ethnic-
ity-speciﬁc differences in the management and outcomes of
NSTEMI were observed, and further studies are needed to
develop strategies to ensure more equitable care for NSTEMI.
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